Govt Job for M.Pharm, M.Sc Job at Institute of Nano Science and Technology

Institute of Nano Science and Technology, Mohali, Punjab, an autonomous institution of Department of Science and Technology, Government of India, has been established under the umbrella of NANO MISSION, initiated by DST to boost research and development in the field of Nanoscience and Nanotechnology in India. INST started its activities on 3rd January 2013, the date on which its first Director was appointed.

Applications are invited from highly motivated and bright candidates for engagement of Project Junior Research Fellow (JRF) in the research project funded by ‘ICMR’, Government of India at Institute of Nano Science and Technology, Mohali.

Post : Junior Research Fellow

Title of the research project : Targeted nanotherapy controlling epigenetic regulation of pediatric solid tumor

Applications Principal Investigator : Dr. Subhasree Roy Choudhury, Scientist-C

Qualifications : M.Sc. Degree in Biological Science / Molecular Biology / Biochemistry, M.Pharm. or M. Tech. degree in Biotechnology/Material Science/Nanoscience & Nanotechnology with valid NET/GATE/GPAT qualification.

Age limit : Must not be over 30 years as on 24.09.2021, which is relaxable for certain reserved categories as per rules of Government of India.

Fellowship : Rs. 31,000/- (pm) + 16% HRA

Project duration : Initially one year and may be extended based on performance of the candidate and availability of funds.

Selection process :
• Completed application in the prescribed format as annexed along with scanned copies of certificates should be sent to ppn@inst.ac.in as a single PDF file by 30.07.2021.

• In addition to the above application, the candidates are required to submit an online synopsis.

• Eligible candidates will be shortlisted for interview, and the date and time of interview will be communicated to the email address provided by candidate.

• Interview will be conducted through google meet and the link for the same will be provided prior to the interview.

General terms and conditions
• The position is purely temporary and on contractual basis and renewable each year subject to satisfactory performance for a maximum of three years. The position is co-terminus with the project. Candidate selected for this position can also apply for the regular PhD program of INST provided they satisfy eligibility criteria.

• No TA/DA will be paid for attending the interview.

• Original documents of age proof/certificates/degrees/mark sheets and other testimonials must be presented along with the self-attested photocopies of these documents at the time of interview.

Only shortlisted candidates will be communicated through email to appear in the interview and no other communication in this regard will be entertained.

Completed applications in the prescribed format as annexed should reach to the following address by 24.09.2021 via email attachment addressed to :
Name and Designation of PI
Dr. Subhasree Roy Choudhury
Scientist-C
Institute of Nanoscience and Technology (INST)
Knowledge City, Sector 81
Mohali-140306, Punjab
Email: subhasreerc@inst.ac.in

Related Posts

  • Pharma
  • April 25, 2025
  • 36 views
250% rally in one year! Multibagger pharma stock jumps despite stock market crash

Stock Marke:  With 250% rally in one year the Multibagger pharma stock gained further on the BSE on Friday, during the intraday trades despite stock market crash. The Sudarshan Pharma…

  • Pharma
  • April 25, 2025
  • 57 views
Laurus Labs Q4 net surges to Rs 234 cr. on higher CDMO revenue

Drugmaker Laurus Labs reported consolidated net profit for the March quarter surged to ₹233.87 crore from ₹75.32 crore a year earlier on a 19% increase in the revenue. Revenue from…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

250% rally in one year! Multibagger pharma stock jumps despite stock market crash

250% rally in one year! Multibagger pharma stock jumps despite stock market crash

Laurus Labs Q4 net surges to Rs 234 cr. on higher CDMO revenue

Laurus Labs Q4 net surges to Rs 234 cr. on higher CDMO revenue

Relief for pharma cos as Delhi HC says cough syrup ban applies prospectively

Relief for pharma cos as Delhi HC says cough syrup ban applies prospectively

Novo Nordisk to phase out country’s largest insulin brand

Novo Nordisk to phase out country’s largest insulin brand